CORRESP Filing
Silo Pharma, Inc.
Date: April 28, 2025 · CIK: 0001514183 · Accession: 0001213900-25-036149
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286777
Letter
Re: Silo Pharma, Inc.
April 28, 2025
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jessica Dickerson
Form S-1 Registration Statement
Filed April 25, 2025
File No. 333-286777
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Silo Pharma, Inc. (the "Company") respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 12:00 p.m., Eastern Daylight Time, on Wednesday, April 30, 2025, or as soon thereafter as possible.
Please notify Richard Friedman of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3031 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
SILO PHARMA, INC.
By: /s/ Eric Weisblum
Name: Eric Weisblum
Title: Chief Financial Officer
Show Raw Text
CORRESP 1 filename1.htm April 28, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Dickerson Re: Silo Pharma, Inc. Form S-1 Registration Statement Filed April 25, 2025 File No. 333-286777 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Silo Pharma, Inc. (the "Company") respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 12:00 p.m., Eastern Daylight Time, on Wednesday, April 30, 2025, or as soon thereafter as possible. Please notify Richard Friedman of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3031 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request. SILO PHARMA, INC. By: /s/ Eric Weisblum Name: Eric Weisblum Title: Chief Financial Officer